Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide.
A chimeric oligonucleotide composed of DNA and modified RNA residues was used to direct correction of the mutation in the hemoglobin betaS allele. After introduction of the chimeric molecule into lymphoblastoid cells homozygous for the betaS mutation, there was a detectable level of gene conversion of the mutant allele to the normal sequence. The efficient and specific conversion directed by chimeric molecules may hold promise as a therapeutic method for the treatment of genetic diseases.
Cole-Strauss
A
A
Department of Pharmacology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, USA.
Yoon
K
K
Xiang
Y
Y
Byrne
B C
BC
Rice
M C
MC
Gryn
J
J
Holloman
W K
WK
Kmiec
E B
EB
D000483:Alleles; D000755:Anemia, Sickle Cell / Q000235:genetics* / Q000628:therapy; D001483:Base Sequence; D002478:Cells, Cultured; D005785:Gene Conversion; D015316:Genetic Therapy; D005914:Globins / Q000235:genetics; D006451:Hemoglobin, Sickle / Q000235:genetics*; D006801:Humans; D008214:Lymphocytes; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000235:genetics*; D009843:Oligoribonucleotides / Q000235:genetics*; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D014162:Transfection
D006451:Hemoglobin, Sickle; D009838:Oligodeoxyribonucleotides; D009843:Oligoribonucleotides; D005914:Globins